The AVATAR Group was established in 2007 by Professor Claire Rickard. Today, AVATAR is a respected independent research group specializing in highly credible scientific research across many vascular access device types and patient settings.
The AVATAR Group undertakes a significant program of clinical trials, laboratory, systematic review and knowledge translation research including health economics, both in Australia and internationally.
The group is currently undertaking several Australian National Health and Medical Research Council (NHMRC) funded trials: the PISCES Trial Peripherally InSerted CEntral catheter Securement; Innovation to improve the experience and outcomes of paediatric central venous access devices: the e-Vascular Access Passport;Peripherally inserted central catheter Innovation to reduCe Infectins and Clots (the PICNIC trial);and DART3: Difficult Access Requires Thought, Training and Technology .
Our base is at Griffith University, Brisbane and Gold Coast, Australia, and we work in partnership with many other universities (including University of Queensland, Queensland University of Technology, and the University of the Sunshine Coast), healthcare organizations and professional groups in Australia and internationally.
No patient or carer wants to experience painful needle punctures to insert vascular access device, or for their device to become blocked, fall out, or to develop a serious infection or blood clot. At AVATAR, we don't think these things should happen either.
Our mission is to make vascular access complications history.